EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of Beauvericin’s activity and mode of action against all life stages of L. tropica for cutaneous Leishmaniasis therapy

Lynn Al Samra, Mohamad El Nahas, Ilham Mneimneh, Aia Sinno, Sima Tokajian, Kelven Rahy, Sergio Thoumi, Lazo Ali, Wael Yammine, Charbel Al Khoury

Frontiers in Cellular and Infection Microbiology · 2025

DOI: 10.3389/fcimb.2025.1599766 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Lynn Al Samra und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Natural Sciences, School of Arts and Sciences, Lebanese American University, Chouran, Beirut, Lebanon. Hauptthemen laut MEDLINE: Leishmania tropica, Leishmaniasis, Cutaneous, Antiprotozoal Agents, Depsipeptides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Leishmaniasis, particularly its cutaneous form caused by Leishmania tropica , remains a significant global health concern due to the limitations of current treatments, including drug resistance, toxicity, and inconsistent efficacy. This study investigates the potential of Beauvericin (BEA), a fungal secondary metabolite, as an alternative antileishmanial agent.

Objectives

This study investigates the potential of Beauvericin (BEA), a fungal secondary metabolite, as an alternative antileishmanial agent.

Methods

We assessed the efficacy of BEA against different developmental stages of L. tropica using in vitro assays and an in vivo Galleria mellonella infection model. The ability of L. tropica to develop resistance to BEA and its effects on the parasite’s gene expression profile were also examined.

Results

BEA exhibited potent antileishmanial activity with equipotency across both promastigote and amastigote stages of L. tropica , with IC 50 values of 0.25 µM and 0.27 µM, respectively, significantly lower than those of miltefosine. Mechanistically, BEA acts as a calcium ionophore, inducing a marked increase in intracellular calcium levels, which serves as the primary cytotoxic event. Transcriptomic profiling further revealed that BEA-induced calcium dysregulation triggers secondary cellular responses involving calcium homeostasis, lipid metabolism, and stress response, contributing to its multifaceted mechanism of action. The G. mellonella model demonstrated that BEA significantly reduced parasite burden, improved survival rates. Notably, BEA showed a slower rate of resistance development compared to ML, indicating its potential as a more sustainable treatment option.

Conclusions

BEA is a promising candidate for antileishmanial therapy, demonstrating superior efficacy, a broad mechanism of action, and a favorable resistance profile compared to ML. Further investigations in mammalian models are warranted to validate BEA’s potential as a novel, cost-effective treatment for leishmaniasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leishmania tropicaLeishmaniasis, CutaneousAntiprotozoal AgentsDepsipeptidesLife Cycle StagesAnimalsDisease Models, AnimalInhibitory Concentration 50Gene Expression ProfilingDrug Resistance

Stichwörter der Autor:innen

BeauvericinGalleria mellonella modelLeishmania tropicaLeishmaniasisRNA-Seqdrug resistance

Substanzen

beauvericinAntiprotozoal AgentsDepsipeptides

Autor:innen und Institutionen

  • Department of Natural Sciences, School of Arts and Sciences, Lebanese American University, Chouran, Beirut, Lebanon.
  • Department of Computer Science and Mathematics, Lebanese American University, Beirut, Lebanon.
  • Department of Natural Sciences, School of Arts and Sciences, Lebanese American University, Byblos, Lebanon.
  • Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Byblos, Lebanon.
  • Department of Plant Protection, Faculty of Agricultural & Veterinary Sciences, Lebanese University, Dekwaneh, Beirut, Lebanon.

Zitieren

APA

Al Samra, L., El Nahas, M., Mneimneh, I., Sinno, A., Tokajian, S., Rahy, K., Thoumi, S., Ali, L., Yammine, W., & Al Khoury, C. (2025). Evaluation of Beauvericin’s activity and mode of action against all life stages of L. tropica for cutaneous Leishmaniasis therapy. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1599766

Vancouver

Al Samra L, El Nahas M, Mneimneh I, Sinno A, Tokajian S, Rahy K, et al. Evaluation of Beauvericin’s activity and mode of action against all life stages of L. tropica for cutaneous Leishmaniasis therapy. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2025.1599766

BibTeX
@article{AlSamra2025,
  author = {Al Samra, Lynn and El Nahas, Mohamad and Mneimneh, Ilham and Sinno, Aia and Tokajian, Sima and Rahy, Kelven and Thoumi, Sergio and Ali, Lazo and Yammine, Wael and Al Khoury, Charbel},
  title = {Evaluation of Beauvericin’s activity and mode of action against all life stages of L. tropica for cutaneous Leishmaniasis therapy},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2025},
  doi = {10.3389/fcimb.2025.1599766}
}
Kostenlos starten →